This quarterly newsletter is dedicated to news about ISPE’s regulatory and quality activities. ISPE is committed to fostering communications and interactions to advance common interests among the pharmaceutical industry and regulatory agencies.
The Regulatory Digest Newsletter
.jpg)
ISPE Regulatory Digest Q3 2023
- EMA Executive Director on the Value of Adaptation, Trust, and Collaboration
- FDA Office of Quality Surveillance on Quality Management Maturity
- EMA on International Cooperation, Harmonization, and Reliance in GMP
- Industry-regulatory discussion panels
ISPE Regulatory Digest Q2 2023
- Barriers to Innovation: Your Input Requested
- ISPE Releases Drug Shortages Prevention Model
- Report on ISPE Work to Support EU HERA
- ISPE Comments on Draft Guidelines
Regulatory Digest Q1 2023
- ISPE Launches Initiative on Enabling Global Pharma Innovation
- Annex 1 Implementation from the Regulators’ Point of View
- Bob Tribe, ISPE Asia-Pacific Regulatory Advisor, Retires
- Your Expertise Can Shape Regulation and Guidance
Regulatory Digest Q4 2022
- ISPE’s Advancing Pharmaceutical Quality (APQ) Program Fully Launched
- ISPE’s APQ Program presented at FDA Advisory Council Meeting on Quality Management Maturity
- ISPE Highlights Pharma 4.0 at PIC/S 50th Anniversary Event
- ISPE Holds Regulatory Summit on Modernizing Inspections
- ISPE Singapore Affiliate Regulatory Panels
- Regulatory Insights from 2022 ISPE Annual Meeting
Regulatory Digest Q3 2022
- Are you ready to implement ICH Q9(R1)?
- ATMP Regulations: Comparison of EudraLex Part IV with PIC/S Annex 2A
- FDA’s Approach to Advancing Quality Surveillance
- EMA on Facilitating Innovative Manufacturing
- Continuous Manufacturing of Drug Substance vs Drug Product
- ISPE’s Asia-Pacific Regulatory Group Re-established
- Quality and Regulatory Challenges, Learnings, and Future Opportunities: ISPE 2022 Annual Meeting
Regulatory Digest Q2 2022
- Regulator/Industry Panels at 2022 ISPE European Annual Conference
- ICH Q2(R2) and Q14 aim to promote more robust analytical processes, greater ease of switching analytical methods post approval
- ISPE Helping Industry Prepare to Implement ICH Q9 Revision
- ISPE Assists Health Canada with ICH Q12 Training
- ISPE’s Advancing Pharmaceutical Quality (APQ) Program Third Guide Released
Regulatory Digest Q1 2022
- Industry Study Finds Divergence in Regulators’ Interpretation of ICH Guidance Related to Control Strategies
- Senior US Pandemic Advisor on Messaging and the Public’s Faith in Pharmaceutical Products
- Path to a Global Dossier: a glimpse of the future?
- Global Regulators Discuss Data Integrity and Real-World Evidence
- ISPE’s Biotechnology Conference and Workshop Featured Several Panel Discussions with Global Regulators
Regulatory Digest Q4 2021
- US FDA and WHO Highlight Agility and Collaboration at 2021 ISPE Annual Meeting & Expo
- Regulators Answer Industry’s Top Questions at 2021 ISPE Annual Meeting Global Regulatory Town Hall
- Regulators Discuss Contemporary Approaches to Drug Shortage Prevention
Regulatory Digest Q3 2021
- Global Regulators and Industry Discuss Shared Responsibility for QRM at ISPE June Summit
- Expanded Coverage of ISPE’s Summit on Remote/Distance Assessments
- ISPE’s PQLI® Initiative helps advance new Regulatory and Technology Approaches
- ISPE’s APQ Program: Management Responsibilities and Review Guide Released
- ISPE Initiatives Support Supply Chain Resiliency
Regulatory Digest 2021 – Q2
- Global Regulators Discuss Remote/Distant Assessments, Audits, and Guidance at ISPE Summit
- ISPE and an Association Group address Annex 1 Implementation Timelines
- ISPE Commences Study on Business Continuity Planning for Drug Shortage Prevention
- Integration of QRM and KM Provide Opportunity for Effective Risk Management
Regulatory Digest 2021 – Q1
- ICH Q12 Implementation Strategies Discussed During Webinar on Challenges and Success of ICH Q12
- 2020 ISPE Annual Meeting & Expo: How Regulators are Responding to COVID-19’s Impact
- Regulatory Panel Addresses COVID-19 Challenges
- Regulators Discuss Distant Assessments During and After COVID-19
- Singapore Affiliate’s 20th Anniversary Conference
- ISPE Singapore Affiliate Interviews HSA’s Sia Chong Hock
- Remote/Distant Assessments, Audits, and Regulatory Guidance
- FDA Commissioner on Lessons Learned from COVID-19
- ISPE Participated in DAF ACT Initiative to Support Domestic Manufacturing of API
- ISPE’s Advancing Pharmaceutical Quality Program Launched
- Drug Shortages: Looking Forward with Regulator Insight
- Business Continuity Planning to Prevent Drug Shortages
- ANVISA training facilitated by ISPE’s Latin America Regulatory Group
- ISPE’s Regulatory Committees, Working Groups, and Initiatives
Regulatory Digest 2020
- Drug Shortages: “Essential” Medicines
- Engaging with Health Authorities to Mitigate & Prevent Drug Shortages
- Drug Shortages: A Challenging Year
- Considerations for Pandemic-related Supply Chains
- ISPE Input to PIC/S GMP Guide Annexes for ATMPs and Biologics
- ISPE’s Input to NASEM Consensus Report